These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34014777)

  • 61. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
    Peters S; Stahel R; Bubendorf L; Bonomi P; Villegas A; Kowalski DM; Baik CS; Isla D; Carpeno JC; Garrido P; Rittmeyer A; Tiseo M; Meyenberg C; de Haas S; Lam LH; Lu MW; Stinchcombe TE
    Clin Cancer Res; 2019 Jan; 25(1):64-72. PubMed ID: 30206164
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
    Kojima Y; Yoshie R; Kawamoto H; Shimo A; Uejima T; Iwatani T; Motoyoshi A; Kanemaki Y; Boku N; Tsugawa K
    Oncology; 2019; 96(6):309-317. PubMed ID: 30893699
    [TBL] [Abstract][Full Text] [Related]  

  • 63. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
    Fujihara M; Shien T; Shien K; Suzawa K; Takeda T; Zhu Y; Mamori T; Otani Y; Yoshioka R; Uno M; Suzuki Y; Abe Y; Hatono M; Tsukioki T; Takahashi Y; Kochi M; Iwamoto T; Taira N; Doihara H; Toyooka S
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884609
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
    Kim SB; Wildiers H; Krop IE; Smitt M; Yu R; Lysbet de Haas S; Gonzalez-Martin A
    Int J Cancer; 2016 Nov; 139(10):2336-42. PubMed ID: 27428671
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prolonged Responses With Trastuzumab Emtasine Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Refractory to Trastuzumab and Pertuzumab: Systematic Review of Evidence.
    Martin Huertas R; Fernández Abad M; Corral de la Fuente E; Serrano Domingo JJ; Martínez Jáñez N
    Clin Breast Cancer; 2021 Oct; 21(5):391-398. PubMed ID: 33549470
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Squires H; Stevenson M; Simpson E; Harvey R; Stevens J
    Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.
    Pondé N; Ameye L; Lambertini M; Paesmans M; Piccart M; de Azambuja E
    Eur J Cancer; 2020 Feb; 126():65-73. PubMed ID: 31923729
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China.
    Zhang H; Zhang Y; Huang C; Wang J
    Clin Drug Investig; 2021 Jun; 41(6):569-577. PubMed ID: 33876415
    [TBL] [Abstract][Full Text] [Related]  

  • 69. T-DM1 for residual, invasive, HER2-positive breast cancer.
    Burki TK
    Lancet Oncol; 2019 Jan; 20(1):e13. PubMed ID: 30555022
    [No Abstract]   [Full Text] [Related]  

  • 70. Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
    Fabi A; Giannarelli D; Moscetti L; Santini D; Zambelli A; Laurentiis M; Caruso M; Generali D; Valle E; Leonardi V; Cannita K; Arpino G; Filippelli G; Ferretti G; Giampaglia M; Montemurro F; Nisticò C; Gasparro S; Cognetti F
    Future Oncol; 2017 Dec; 13(30):2791-2797. PubMed ID: 29182361
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer.
    Wuerstlein R; Ellis P; Montemurro F; Antón Torres A; Delaloge S; Zhang Q; Wang X; Wang S; Shao Z; Li H; Rachman A; Vongsaisuwon M; Liu H; Fear S; Peña-Murillo C; Barrios C
    ESMO Open; 2022 Oct; 7(5):100561. PubMed ID: 36084395
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 73. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
    Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
    Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial.
    Yan H; Yu K; Zhang K; Liu L; Li Y
    Oncotarget; 2017 Nov; 8(60):102458-102467. PubMed ID: 29254261
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
    Lu D; Girish S; Gao Y; Wang B; Yi JH; Guardino E; Samant M; Cobleigh M; Rimawi M; Conte P; Jin JY
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):399-410. PubMed ID: 24939213
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels.
    Barfield RM; Kim YC; Chuprakov S; Zhang F; Bauzon M; Ogunkoya AO; Yeo D; Hickle C; Pegram MD; Rabuka D; Drake PM
    Mol Cancer Ther; 2020 Sep; 19(9):1866-1874. PubMed ID: 32651200
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine.
    Imamura M; Morimoto T; Egawa C; Fukui R; Bun A; Ozawa H; Miyagawa Y; Fujimoto Y; Higuchi T; Miyoshi Y
    Sci Rep; 2019 Feb; 9(1):1811. PubMed ID: 30755651
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy.
    Ji D; Shen W; Zhang J; Cao J; Li W; Lam LH; Wu F; Wang B; Li Z; Sun G; Hu X; Chen SC
    Medicine (Baltimore); 2020 Oct; 99(44):e22886. PubMed ID: 33126339
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.
    Jacot W; Cottu P; Berger F; Dubot C; Venat-Bouvet L; Lortholary A; Bourgeois H; Bollet M; Servent V; Luporsi E; Espié M; Guiu S; D'Hondt V; Dieras V; Sablin MP; Brain E; Neffati S; Pierga JY; Bidard FC
    Breast Cancer Res; 2019 Nov; 21(1):121. PubMed ID: 31727113
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
    Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
    Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.